Organization · Venture Capital
Receptor Partners, LLC
Receptor Partners, LLC is a New York-based venture capital firm focused on investing in the psychedelic medicine sector, targeting companies developing therapeutic solutions in this niche.
Overview
What Receptor Partners, LLC does
What Receptor Partners, LLC is
Receptor Partners, LLC is a New York-based venture capital firm focused on investing in the psychedelic medicine sector, targeting companies developing therapeutic solutions in this niche.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2021
- Approximate age
- About 5 years
- Structured capabilities
- Funder
- Last reviewed
- April 26, 2026
Official channels
Find Receptor Partners, LLC elsewhere
Open the official website or a supported primary organization account.
Capability profile
Receptor Partners, LLC as a funder
Investment thesis
Receptor Partners invests in companies building therapeutic solutions in the psychedelic-treatment ecosystem, focusing on regulated psychedelic or psychedelic-inspired therapeutics, CNS drug discovery, and related mental-health biotechnology.
Focus narrative
Receptor Partners invests in companies within the psychedelic medicine sector, targeting those that are developing regulated psychedelic or psychedelic-inspired therapeutics, CNS drug discovery, and mental health biotechnology. The firm is particularly interested in early-stage ventures that are working on innovative drug delivery systems and therapeutic solutions.
Value beyond capital
Receptor Partners adds value to its portfolio companies by providing strategic guidance and support in navigating the complex landscape of psychedelic medicine. The firm leverages its expertise in drug delivery and regulatory pathways to help companies develop differentiated therapeutic solutions that address critical challenges in the field.
Focus and fit
- Stages
- Seed · Series A · Friends and Family · Accelerator
- Regions
- North AmericaEurope
Availability
- Currently deploying
- Not published
Portfolio and track record
- Recorded portfolio count
- 8
Portfolio context
Notable portfolio companies include: Beckley Psytech: Developing psychedelic compounds for neurological and psychiatric disorders. Psilera: A biopharmaceutical company focused on psychedelic-derived neuromodulators for neurological therapeutics. Mind State Design: Designing psychedelic-inspired therapies for mental health conditions. Bright Minds Biosciences: Focused on serotonergic drug candidates in neuropsychiatric disease. Tactogen: Developing psychedelic or empathogenic medicines. Delix Therapeutics: Creating neuroplasticity-promoting therapeutics. Freedom Bio: Engaged in psychedelic medicine development. Cybin: A public company focused on psychedelic therapeutics.
Common questions
What to know about Receptor Partners, LLC
Upseed classifies Receptor Partners, LLC under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 26, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.